Renal impairment (RI) is a poor prognostic factor in patients with multiple myeloma (MM). Despite improvements in survival with the introduction of novel therapies in recent years, RI remains one of the most common complications with an incidence of 20% to 50% at diagnosis, and approximately 5% to 10% of MM patients are dialysis-dependent.1-3 The...Continue Reading

A Phase II study of a GlaxoSmithKline drug to treat the blood cancer multiple myeloma has been successful, the company said Friday. The London-based drugmaker said it had positive headline results from the DREAMM-2 study of GSK2857916 (belantamab mafodotin), an antibody-drug conjugate that targets the antigen BCMA. It did not provide details of the data, but said...Continue Reading